- Home
- ESSA vs CHRS Comparison
ESSA vs CHRS Comparison
Compare ESSA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESSA
- CHRS
- Stock Information
- Founded
- ESSA 1916
- CHRS 2010
- Country
- ESSA United States
- CHRS United States
- Employees
- ESSA N/A
- CHRS N/A
- Industry
- ESSA Banks
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESSA Finance
- CHRS Health Care
- Exchange
- ESSA Nasdaq
- CHRS Nasdaq
- Market Cap
- ESSA 206.9M
- CHRS 185.5M
- IPO Year
- ESSA N/A
- CHRS 2014
- Fundamental
- Price
- ESSA $19.50
- CHRS $1.52
- Analyst Decision
- ESSA
- CHRS Strong Buy
- Analyst Count
- ESSA 0
- CHRS 4
- Target Price
- ESSA N/A
- CHRS $5.38
- AVG Volume (30 Days)
- ESSA 13.4K
- CHRS 10.1M
- Earning Date
- ESSA 01-22-2025
- CHRS 11-06-2024
- Dividend Yield
- ESSA 3.08%
- CHRS N/A
- EPS Growth
- ESSA N/A
- CHRS N/A
- EPS
- ESSA 1.78
- CHRS N/A
- Revenue
- ESSA $67,843,000.00
- CHRS $304,340,000.00
- Revenue This Year
- ESSA N/A
- CHRS $1.64
- Revenue Next Year
- ESSA N/A
- CHRS $16.98
- P/E Ratio
- ESSA $10.96
- CHRS N/A
- Revenue Growth
- ESSA N/A
- CHRS 44.19
- 52 Week Low
- ESSA $15.29
- CHRS $0.66
- 52 Week High
- ESSA $21.50
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- ESSA 43.34
- CHRS 52.47
- Support Level
- ESSA $19.58
- CHRS $1.45
- Resistance Level
- ESSA $20.30
- CHRS $1.85
- Average True Range (ATR)
- ESSA 0.54
- CHRS 0.23
- MACD
- ESSA -0.15
- CHRS -0.03
- Stochastic Oscillator
- ESSA 23.53
- CHRS 3.88
About ESSA ESSA Bancorp Inc.
ESSA Bancorp Inc is a holding company, engaged in accepting deposits from the general public and investing those deposits, together with funds generated from operations and borrowings, in residential first mortgage loans (including construction mortgage loans), commercial real estate loans, home equity loans and lines of credit and commercial and industrial loans. The company offers a variety of deposit accounts, including checking, savings and certificates of deposit. The company also offers asset management and trust services and investment services. The company also offers insurance benefit consulting services through its wholly-owned subsidiary, ESSA Advisory Services, LLC.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.